acamprosate has been researched along with Alcohol-Related Disorders in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (36.11) | 29.6817 |
| 2010's | 22 (61.11) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Anton, RF; Falk, DE; Hasin, DS; Heather, N; Kranzler, HR; Litten, RZ; Mann, KF; O'Malley, SS; Witkiewitz, K | 1 |
| Lyon, J | 1 |
| Bramness, JG; Heldal, AT; Lobmaier, PPK; Skurtveit, S; Vederhus, JK | 1 |
| Harris, AHS; Matson, TE; Williams, EC | 1 |
| Kranzler, HR; Zindel, LR | 1 |
| Knudsen, HK; Roman, PM | 2 |
| Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R | 1 |
| Borro, P; Leone, S; Testino, G | 1 |
| Frohe, T; Kirouac, M; Maisto, SA; McCallion, E; Vowles, KE; Witkiewitz, K | 1 |
| Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J | 1 |
| Biernacka, JM; Choi, DS; Frye, MA; Geske, JR; Hinton, DJ; Ho, AM; Karpyak, VM; Nam, HW; Prieto, ML; Weinshilboum, RM | 1 |
| Higuchi, S; Yumoto, Y | 1 |
| Helton, SG; Lohoff, FW | 1 |
| Bramness, JG; Mann, K; Wurst, FM | 1 |
| Bowe, T; Christopher, M; Finlay, AK; Gidwani, R; Hagedorn, H; Harris, AH; Kay, C; Nevedal, A; Rosen, C | 1 |
| Crits-Christoph, P; Gallop, R; Gastfriend, DR; Gibbons, MB; Lundy, C; Markell, HM; Stringer, M | 1 |
| Bilbao, A; Kiefer, F; Pawlak, CR; Perreau-Lenz, S; Spanagel, R; Vengeliene, V; von der Goltz, C | 1 |
| Franck, J; Hammarberg, A; Jayaram-Lindström, N; Nylander, I; Reid, MS; Zhou, Q | 1 |
| Aldridge, A; Bray, JW; Cisler, RA; Couper, D; McKay, JR; Mills, M; O'Malley, S; Zarkin, GA | 1 |
| Hackl-Herrwerth, A; Lehert, P; Leucht, S; Rösner, S; Soyka, M; Vecchi, S | 1 |
| Hunter-Reel, D; Witkiewitz, K; Zweben, A | 1 |
| Spanagel, R; Vengeliene, V | 1 |
| Clark, DB | 1 |
| Blodgett, JC; Finney, JW; Humphreys, K; Maisel, NC; Wilbourne, PL | 1 |
| Kenna, GA; McGeary, JE; Swift, RM | 1 |
| Williams, SH | 1 |
| Bell, JR; Haber, PS; Morley, KC; Phung, N; Reid, SC; Richardson, K; Sannibale, C; Teesson, M; Thomson, C; Weltman, M | 1 |
| Swift, R | 1 |
| McDonough, KP | 1 |
| Peterson, AM | 1 |
| Brunette, MF; Drake, RE; Green, AI; Noordsy, DL | 1 |
| Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M | 1 |
| Fiellin, DA; O'Connor, PG; Reid, MC | 1 |
| Tedeschi, M | 1 |
16 review(s) available for acamprosate and Alcohol-Related Disorders
| Article | Year |
|---|---|
Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Clinical Trials as Topic; Disulfiram; Naltrexone; Practice Patterns, Physicians'; Topiramate; United States; United States Department of Veterans Affairs; Veterans | 2019 |
Pharmacotherapy of alcohol use disorders: seventy-five years of progress.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Fructose; Humans; Hypnotics and Sedatives; Narcotic Antagonists; Pharmacogenetics; Taurine; Topiramate | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2014 |
Treatment of alcohol dependence: recent progress and reduction of consumption.
Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking; Contraindications; Craving; Disulfiram; Drugs, Investigational; Europe; Humans; Meta-Analysis as Topic; Multicenter Studies as Topic; Naltrexone; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Sodium Oxybate; Taurine | 2014 |
[Pharmacological therapies for alcohol use disorder in Japan].
Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2015 |
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Disulfiram; Fructose; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Taurine; Topiramate; United States | 2015 |
Acamprosate for alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Diarrhea; Humans; Placebo Effect; Randomized Controlled Trials as Topic; Taurine | 2010 |
New pharmacological treatment strategies for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Disulfiram; Drugs, Investigational; History, 18th Century; History, 21st Century; Humans; Naltrexone; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine | 2013 |
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Ethanol; Humans; Inactivation, Metabolic; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Time Factors; Treatment Outcome | 2013 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Clinical Trials as Topic; Disulfiram; Excitatory Amino Acid Antagonists; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Medications for treating alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Disulfiram; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; Treatment Outcome | 2005 |
Emerging approaches to managing alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Brain; Disulfiram; Drug Therapy, Combination; Ethanol; Humans; Naltrexone; Taurine | 2007 |
Improving adherence in patients with alcohol dependence: a new role for pharmacists.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Disulfiram; Humans; Naltrexone; Patient Compliance; Pharmacists; Professional Role; Taurine; Treatment Refusal | 2007 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate | 2008 |
New therapies for alcohol problems: application to primary care.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Primary Health Care; Psychotherapy; Research Design; Taurine; United States | 2000 |
Naltrexone and acamprosate. Using new drugs for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Australia; Clinical Trials as Topic; Female; Guidelines as Topic; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Satisfaction; Prognosis; Taurine; Treatment Outcome | 2001 |
6 trial(s) available for acamprosate and Alcohol-Related Disorders
| Article | Year |
|---|---|
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Female; Health Surveys; Humans; Male; Mental Health; Middle Aged; Motivational Interviewing; Naltrexone; Risk; Treatment Outcome; United Kingdom; United States; World Health Organization | 2020 |
Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Cross-Sectional Studies; Health Plan Implementation; Humans; Information Dissemination; Taurine; Treatment Outcome; United States; United States Substance Abuse and Mental Health Services Administration | 2014 |
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therapy; Chronic Pain; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Pain Measurement; Recurrence; Taurine; Treatment Outcome | 2015 |
The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin.
Topics: Acamprosate; Adrenocorticotropic Hormone; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; beta-Endorphin; Double-Blind Method; Female; Hormones; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Pituitary-Adrenal System; Taurine; Time Factors; Treatment Outcome | 2009 |
Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Forecasting; Humans; Male; Middle Aged; Naltrexone; Social Support; Spouses; Taurine; Treatment Outcome | 2012 |
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety; Australia; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Secondary Prevention; Taurine; Treatment Outcome | 2006 |
14 other study(ies) available for acamprosate and Alcohol-Related Disorders
| Article | Year |
|---|---|
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
Use of drugs for alcohol use disorder in Norway 2004–16.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Drug Prescriptions; Drug Utilization; Female; Humans; Male; Middle Aged; Naltrexone; Norway; Registries | 2018 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States | 2015 |
Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biomarkers; Glutamic Acid; Humans; Taurine; Treatment Outcome | 2015 |
The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Humans; Insurance Carriers; Longitudinal Studies; Medicaid; Patient Protection and Affordable Care Act; Substance Abuse Treatment Centers; Taurine; United States | 2016 |
Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe.
Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Europe; Humans; Marketing; Naltrexone; Narcotic Antagonists; Perception; Practice Guidelines as Topic; Societies, Medical; Surveys and Questionnaires; Taurine; Treatment Outcome | 2016 |
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Taurine; Topiramate; United States; United States Department of Veterans Affairs; Veterans; Young Adult | 2016 |
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Missouri; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Psychotherapy; Taurine | 2016 |
Cue-induced alcohol-seeking behaviour is reduced by disrupting the reconsolidation of alcohol-related memories.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Anisomycin; Behavior, Addictive; Behavior, Animal; Conditioning, Operant; Cues; Dizocilpine Maleate; Ethanol; Male; Memory; Mental Recall; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Self Administration; Taurine | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome | 2009 |
The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
Topics: Acamprosate; Accidents, Traffic; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Costs and Cost Analysis; Crime; Health Services; Humans; Naltrexone; Taurine | 2010 |
Pharmacotherapy for adolescent alcohol use disorder.
Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central Nervous System Stimulants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Taurine | 2012 |
Alcohol dependence and pharmacologic treatment. Introduction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Humans; Naltrexone; Taurine; United States | 2007 |
Schizophrenia and co-occurring substance use disorder.
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Humans; Ill-Housed Persons; Male; Naltrexone; Schizophrenia; Substance-Related Disorders; Taurine | 2007 |